Using Hi-C, genome sequencing, and optical mapping, researchers profiled structural variants in multiple cancer cell lines, leading to potential non-coding drivers.
The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.
With its Direct Labeling and Staining (DLS) chemistry, currently available to early-access users, Bionano is pushing forward with more contiguous genome maps.
At PAG, researchers from the Rockefeller University Vertebrate Genome Laboratory outlined sequencing and assembly strategies for phase 1 of the VGP G10K.
After more than two years of development, the British vendor has matched HPC for sequencing alignment accuracy, at far lower power consumption.
The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
Increasingly, researchers are combining sequencing, mapping, and scaffolding technologies to generate more contiguous and accurate reference genomes.
The public-private consortium, led by the National Institute of Standards and Technology, recently released four new reference materials.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.